Selexys

What makes a PhII drug worth up to $665M? Researchers spell it out for Novartis
Endpoints
Mon, 12/5/16 - 09:48 am
Novartis
crizanlizumab
sickle cell disease
M&A
Selexys
Novartis buys sickle cell player Selexys in $665M deal
Fierce Biotech
Mon, 11/21/16 - 11:34 am
Novartis
Selexys
M&A
sickle cell disease